It took three tries, but Outlook Therapeutics finally got the green light from the FDA. On Friday, the agency approved the company's ONS-5010/LYTENAVA (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD), or wet AMD. That makes LYTENAVA the first and only FDA-approved ophthalmic formulation of bevacizumab designed specifically for wet AMD in the United States.

This is a big deal because bevacizumab—the active ingredient in Avastin—has been used off-label in ophthalmology for over two decades. Retina specialists have been injecting a cancer drug into people's eyes, essentially, because it works and costs less than the branded alternatives. But until now, there was no version specifically made for the eye. Doctors had to rely on repackaged doses originally intended for intravenous use, which raised concerns about consistency and sterility.

LYTENAVA changes that. It's a purpose-built ophthalmic formulation designed for intravitreal injection, meaning it's made to go directly into the eye. The FDA approval means it meets the agency's standards for manufacturing quality and regulatory oversight.

“For more than two decades, bevacizumab has served as one of the most widely utilized anti-VEGF therapies in retina care despite the absence of an FDA-approved ophthalmic formulation. LYTENAVA fundamentally changes that landscape,” said Bob Jahr, CEO of Outlook Therapeutics. “Rather than relying on repackaged formulations originally intended for intravenous use, physicians now have access to a purpose-built ophthalmic formulation of bevacizumab designed specifically for intravitreal administration that delivers the manufacturing consistency, product quality, and regulatory oversight patients deserve.”

The approval also comes with a nice regulatory perk: Outlook Therapeutics expects to secure 12 years of Reference Product Exclusivity under the Biologics Price Competition and Innovation Act. That means no biosimilar competition for over a decade, which is a big deal in the biologics world.

Wet AMD is a chronic, progressive disease and a leading cause of severe vision loss in older adults. Patients often need ongoing treatment for years, so having a reliable, FDA-approved option matters. The U.S. anti-VEGF retina market is worth about $8.5 billion annually, with millions of injections performed each year. LYTENAVA is stepping into that market, aiming to become the go-to bevacizumab therapy.

Outlook Therapeutics is now moving into commercial mode. The company is building a specialized retina sales team, working on reimbursement strategies, and trying to make LYTENAVA accessible to patients nationwide before the end of the year.

As for the stock? It didn't get a post-approval pop. Shares were down about 9.6% to $1.27 on Monday, according to market data. Maybe investors were expecting a bigger splash, or perhaps they're focused on the execution risk ahead. But for a company that had been rejected three times by the FDA, finally getting a yes is a milestone worth noting.